Condition (MeSH)
Post-Lyme Disease Syndrome
ClinicalTrials.gov lists 21 trials for Post-Lyme Disease Syndrome or a narrower condition beneath it. AI Agent Vault, Inc. d/b/a Precision Mito has the most among industry and government lead sponsors, with 1.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
21 of the 21 trials are tagged with Post-Lyme Disease Syndrome itself; the rest are tagged with a narrower condition beneath it.
When did Post-Lyme Disease Syndrome trials start? (9)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 2/3
- Not applicable
- Observational
- Unknown
Top of scale: 5
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 2 |
| 2025 | 2 |
| 2024 | 3 |
| 2023 | 3 |
| 2022 | 3 |
| 2021 | 1 |
| 2020 | 1 |
| 2019 | 5 |
| 2015 | 1 |
No forecast is made for this condition: it averages 2.4 trial starts a year over the five years to September, under the 5 a year the method needs.
Prediction, not a registry value: median of 33 months from start to primary completion across 5 trials still running at the 2026-10-09 snapshot; registered median of 28 months across 7 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Post-Lyme Disease Syndrome trials in? (7)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 2 |
| Phase 1/2 | 4 |
| Phase 2 | 1 |
| Phase 2/3 | 1 |
| Not applicable | 6 |
| Observational | 6 |
| Unknown | 1 |
How many Post-Lyme Disease Syndrome trials are recruiting? (6)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 1 |
| Recruiting | 8 |
| Completed | 6 |
| Suspended | 2 |
| Terminated | 1 |
Showing 5 of 6 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Post-Lyme Disease Syndrome trials? (1)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| AI Agent Vault, Inc. d/b/a Precision Mito | 1 |
Which drugs are being tested for Post-Lyme Disease Syndrome? (2)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Lumbrokinase | 1 |
| Disulfiram | 1 |
Interventions as named in the registry (5)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Ceftriaxone 4g/ 24h | 2 |
| Dextrose 5 | 1 |
| There is no intervention in this study. | 1 |
| Tetracycline hydrochloride 3% | 1 |
| IV Psilocybin | 1 |
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Post-Lyme Disease Syndrome trials report? (2)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| ER visit | 1 | 1 |
| Short-term hospitalization | 1 | 1 |
Which publications cover Post-Lyme Disease Syndrome? (1)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Post-treatment Lyme disease symptoms score: Developing a new tool for research. | PloS one | 2019 | Yes |
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence, rare-disease identity, and sub-conditions in mesh.